Stifel raised the firm’s price target on AnaptysBio (ANAB) to $80 from $55 and keeps a Buy rating on the shares. Phase 2 induction data for rosnilimab in UC due in November to December represents “the next major catalyst” for the company and the PD-1 agonist/depleter class, says the analyst, who thinks a signal in line with standard of care first-line biologics “would represent a clear win with potential to deepen over time” and thinks shares could trade to $70-$80 in such a scenario.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio price target raised to $70 from $45 at Wedbush
- Positive Outlook for AnaptysBio: Strategic Developments and Promising Trial Results Drive Buy Rating
- AnaptysBio initiated with an Overweight at Barclays
- Trump announces lumber tariffs, Exxon Mobil to cut 2,000 jobs: Morning Buzz
- Strategic Split and Promising Pipeline: AnaptysBio’s Path to Growth and Value Maximization